Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Maju Mathews, Srihari Gopal, Isaac Nuamah, Ludger Hargarter, Adam J Savitz, Edward Kim, Wilson Tan, Bernardo Soares & Christoph U Correll. (2019) Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia. Neuropsychiatric Disease and Treatment 15, pages 1365-1379.
Read now
Read now
Hayriye Dilek Hamurcu, Ali Caykoylu, Eda Peksen, Mehmet Ozturk & Neslihan Sevil. (2016) A Case of Chronic Schizophrenia Who were Switched from Combined Treatment to Monotherapy and Achieved a Decrease in Positive Symptoms after Lowering the Clozapine Dose. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology 26:3, pages 324-328.
Read now
Read now
Roger M Pinder. (2012) Editor’s choice. Neuropsychiatric Disease and Treatment 8, pages 321-322.
Read now
Read now
Articles from other publishers (12)
Teresa Margraff, Georgios Schoretsanitis, Irene Neuner, Ekkehard Haen, Arnim Johannes Gaebler & Michael Paulzen. (2023) Discovering interactions in augmentation strategies: Impact of duloxetine on the metabolism of aripiprazole. Basic & Clinical Pharmacology & Toxicology.
Crossref
Crossref
Pradilka Perera, Ganeya Gajaram, Danish Qureshi, Manpreet Gill, Amod Thanju, Afrina Zaman, Patrice Fouron & Ayodeji Jolayemi. (2022) Use of Bupropion in the Management of Negative Symptom Schizophrenia: A Case Series. Cureus.
Crossref
Crossref
Ashwin Kumar N, Gowri Annasamy, Pavani Rekulapally, Suresh S N & Saravanan Krishnan. 2022. Applications of Nanotechnology in Drug Discovery and Delivery. Applications of Nanotechnology in Drug Discovery and Delivery
255
289
.
Olena Khaustova & Dmytro Assonov. (2021) The use of antipsychotics in targeted therapy of schizophrenia — prospects and challenges (for example, amisulpride).. Ukrains'kyi Visnyk Psykhonevrolohii:Volume 29, issue 2 (107), pages 83-89.
Crossref
Crossref
Hiroshi Kimura, Nobuhisa Kanahara & Masaomi Iyo. (2021) Rationale and neurobiological effects of treatment with antipsychotics in patients with chronic schizophrenia considering dopamine supersensitivity. Behavioural Brain Research 403, pages 113126.
Crossref
Crossref
Valeria Calsolaro, Grazia Daniela Femminella, Sara Rogani, Salvatore Esposito, Riccardo Franchi, Chukwuma Okoye, Giuseppe Rengo & Fabio Monzani. (2021) Behavioral and Psychological Symptoms in Dementia (BPSD) and the Use of Antipsychotics. Pharmaceuticals 14:3, pages 246.
Crossref
Crossref
Sundar Mahajan, Dilpreet Singh, Rashi Sharma, Gurdeep Singh & Neena Bedi. (2021) pH-Independent Dissolution and Enhanced Oral Bioavailability of Aripiprazole-Loaded Solid Self-microemulsifying Drug Delivery System. AAPS PharmSciTech 22:1.
Crossref
Crossref
Michael A. Cummings, George J. Proctor & Ai-Li W. Arias. (2019) Dopamine antagonist antipsychotics in diverted forensic populations. CNS Spectrums 25:2, pages 128-135.
Crossref
Crossref
G. Sulejmanpasic, S. Bise, A. Toskic & F. Pepic. (2019) P.104 Olanzapine augmented with aripiprazole in treatment-resistant schizophrenia. European Neuropsychopharmacology 29, pages S89-S90.
Crossref
Crossref
M. V. Ivanov & D. S. Zubov. (2019) Electroconvulsive therapy in treatment of resistant schizophrenia: biological markers of efficacy and safety. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova 119:3, pages 92.
Crossref
Crossref
Manit Srisurapanont, Sirijit Suttajit, Narong Maneeton & Benchalak Maneeton. (2015) Efficacy and safety of aripiprazole augmentation of clozapine in schizophrenia: A systematic review and meta-analysis of randomized-controlled trials. Journal of Psychiatric Research 62, pages 38-47.
Crossref
Crossref
Andrea de Bartolomeis, Livia Avvisati, Felice Iasevoli & Carmine Tomasetti. (2013) Intracellular pathways of antipsychotic combined therapies: Implication for psychiatric disorders treatment. European Journal of Pharmacology 718:1-3, pages 502-523.
Crossref
Crossref